Emily
Editor, Senior Moderator
https://www.cancertherapyadvisor.co...ene-therapy-revival-with-off-shelf-potential/
June 13, 2019
The Revival of a Forgotten Cancer Gene Therapy With Off-the-Shelf Potential
Christina Bennett, MS
A seemingly forgotten, off-the-shelf cancer gene therapy from the early 2000s appears to be getting a revival. Eight cancer patients who received the therapy a decade ago are still alive, and the features of these super responders were reported at the 2019 American Society of Gene and Cell Therapy (ASGCT) annual meeting in Washington, D.C.[SUP]1,2[/SUP] And now, phase 2 trials are being planned to further evaluate the therapy.
The tumor-targeted gene therapy, known as DeltaRex-G (formerly Rexin-G), works by delivering a retroviral vector to tumor cells that encodes for an anticyclin G1 construct that is meant to inhibit the cyclin G1 gene (CCNG1), leading to cell death. The first-in-human study was conducted in the Philippines in 2002 with patients who had chemotherapy-resistant solid tumors...
June 13, 2019
The Revival of a Forgotten Cancer Gene Therapy With Off-the-Shelf Potential
Christina Bennett, MS
A seemingly forgotten, off-the-shelf cancer gene therapy from the early 2000s appears to be getting a revival. Eight cancer patients who received the therapy a decade ago are still alive, and the features of these super responders were reported at the 2019 American Society of Gene and Cell Therapy (ASGCT) annual meeting in Washington, D.C.[SUP]1,2[/SUP] And now, phase 2 trials are being planned to further evaluate the therapy.
The tumor-targeted gene therapy, known as DeltaRex-G (formerly Rexin-G), works by delivering a retroviral vector to tumor cells that encodes for an anticyclin G1 construct that is meant to inhibit the cyclin G1 gene (CCNG1), leading to cell death. The first-in-human study was conducted in the Philippines in 2002 with patients who had chemotherapy-resistant solid tumors...
